

**PATIENT HISTORY:**

CHIEF COMPLAINT/ PRE-OP/ POST-OP DIAGNOSIS: Left breast cancer.

LMP DATE: Not applicable.

PROCEDURE: Left segmental mastectomy with wire localization, sentinel node biopsy and mapping.

SPECIFIC CLINICAL QUESTION: Not provided.

OUTSIDE TISSUE DIAGNOSIS: No.

PRIOR MALIGNANCY: No.

CHEMORADIATION THERAPY: No.

OTHER DISEASES: No

ICD-0-3

Carcinoma, infiltrating ductal, NOS 8500/3

Site: breast, NOS C50.9 /w 3/28/11

**FINAL DIAGNOSIS:**

Collection Date:

PART 1: LYMPH NODE, LEFT AXILLA, SENTINEL NODE #1, BIOPSY -  
ONE BENIGN LYMPH NODE, NO EVIDENCE OF MALIGNANCY (0/1).PART 2: LYMPH NODE, LEFT AXILLA, SENTINEL NODE #2, BIOPSY -  
ONE BENIGN LYMPH NODE, NO EVIDENCE OF MALIGNANCY (0/1).

PART 3: BREAST, LEFT, SEGMENTAL MASTECTOMY WITH WIRE LOCALIZATION -

- A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR FORMATION: 3, NUCLEAR PLEOMORPHISM: 2, MITOTIC ACTIVITY: 2; TOTAL SCORE 7/9).
- B. INVASIVE TUMOR MEASURES 1.5 CM IN GREATEST DIMENSION (GROSS MEASUREMENT).
- C. LYMPHOVASCULAR SPACE INVASION IS PRESENT.
- D. DUCTAL CARCINOMA IN-SITU (DCIS), NUCLEAR GRADE 2, SOLID TYPE..
- E. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA; CARCINOMA IS 2 MM FROM NEAREST (ANTERIOR) MARGIN.
- F. FIBROCYSTIC CHANGES, DUCTAL EPITHELIAL HYPERPLASIA AND SCLEROSING ADENOSIS.
- G. BIOPSY SITE CHANGES.
- H. CALCIFICATIONS ASSOCIATED WITH BENIGN AND MALIGNANT AREAS.
- I. TUMOR REPORTED TO BE POSITIVE FOR ER AND PR, AND NEGATIVE FOR HER-2/NEU

J. PATHOLOGIC STAGE: pT1a pN0.

**SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST**

LATERALITY: Left  
 PROCEDURE: Segmental  
 LOCATION: Clock position: 12:00  
 SIZE OF TUMOR: Maximum dimension invasive component: 15 mm  
 MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: No  
 TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS  
 NOTTINGHAM SCORE: Nuclear grade: 2  
 Tubule formation: 3  
 Mitotic activity score: 2  
 Total Nottingham score: 7  
 Nottingham grade (1, 2, 3): 2  
 ANGIOLYMPHATIC INVASION: Yes  
 DERMAL LYMPHATIC INVASION: Not applicable  
 CALCIFICATION: Yes, benign zones  
 Yes, malignant zones  
 TUMOR TYPE, IN SITU: Solid  
 Percent of tumor occupied by in situ component: 10 %  
 SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: No  
 Distance of invasive tumor to closest margin: 3 mm  
 SURG MARGINS INVOLVED BY IN SITU COMPONENT: No  
 Distance of in situ disease to closest margin: 2 mm  
 LYMPH NODES POSITIVE: 0  
 LYMPH NODES EXAMINED: 2  
 METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain  
 T STAGE, PATHOLOGIC: pT1a  
 N STAGE MODIFIER: (sn)  
 N STAGE, PATHOLOGIC: pN0  
 M STAGE: Not applicable  
 ESTROGEN RECEPTORS: positive, H-score: 205  
 PROGESTERONE RECEPTORS: positive, H-score: 225  
 HER2/NEU: 1+

 UUID: 6AE92F6F-E29D-4386-AF1E-F15728C1AAE8  
 TCGA-BH-A281-01A-PR

Redacted



Criteria	Yes	No
Diagnosis Discrepancy		
Primary Tumor Site Discrepancy		
HIPAA Discrepancy		
Prior Malignancy History		
Dual/Synchronous Primary Notes		
Case is (circle):		
Reviewer Initials		
Date Reviewed		